Latest Breaking News On - Stoke therapeutics daily - Page 2 : comparemela.com

HC Wainwright Brokers Cut Earnings Estimates for Stoke Therapeutics, Inc (NASDAQ:STOK)

HC Wainwright Brokers Cut Earnings Estimates for Stoke Therapeutics, Inc (NASDAQ:STOK)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesSg americas securitiesStoke therapeutics incJpmorgan chase coStoke therapeutics company profileMirae asset global investments coSecurities exchange commissionDorsey whitney trustCanaccord genuity groupNeedham companyYork mellon corpStoke therapeuticsFree reportStoke therapeuticGenuity groupTherapeutics trading down

Stoke Therapeutics, Inc (NASDAQ:STOK) Forecasted to Post FY2028 Earnings of $0 17 Per Share

Stoke Therapeutics, Inc (NASDAQ:STOK) Forecasted to Post FY2028 Earnings of $0 17 Per Share
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesStephenj tulipanoStoke therapeutics incStoke therapeutics company profileJpmorgan chase coCantor fitzgeraldNeedham companyCanaccord genuity groupCapital partnersMirae asset global investments coSecurities exchange commissionStoke therapeuticsFree reportStoke therapeuticGet free reportTherapeutics stock down

Stoke Therapeutics, Inc (NASDAQ:STOK) Receives Consensus Rating of Moderate Buy from Brokerages

Stoke Therapeutics, Inc (NASDAQ:STOK) Receives Consensus Rating of Moderate Buy from Brokerages
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesCapital partnersStoke therapeutics incJpmorgan chase coSecurities exchange commissionMirae asset global investments coStoke therapeutics company profileCantor fitzgeraldStoke therapeuticsGet free reportSkorpios trustExchange commissionAsset global investmentsTrexquant investmentGet freeStoke therapeutics daily

Stoke Therapeutics (NASDAQ:STOK) Given New $20 00 Price Target at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) Given New $20 00 Price Target at Canaccord Genuity Group
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesCantor fitzgeraldSecurities exchange commissionSg americas securitiesDorsey whitney trustJpmorgan chase coSherbrooke park advisersCorton capital incStoke therapeutics incCanaccord genuity groupStoke therapeutics company profileStoke therapeuticsGet free reportGenuity groupExchange commissionSkorpios trust

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20 00 at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20 00 at Canaccord Genuity Group
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesStephenj tulipanoMirae asset global investments coSecurities exchange commissionCantor fitzgeraldCorton capital incJpmorgan chase coStoke therapeutics incCapital partnersCanaccord genuity groupStoke therapeutics company profileStoke therapeuticsGet free reportGenuity groupExchange commissionAsset global investments